Clinical Efficacy of Renal Failure Enema as an Adjuvant Therapy for Chronic Kidney Disease Stages 3-4 and Its Effect on Blood IS， PCS， and TMAO

WANG Jing; ZHANG Mianzhi

doi:10.13422/j.cnki.syfjx.20250495

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Renal Failure Enema as an Adjuvant Therapy for Chronic Kidney Disease Stages 3-4 and Its Effect on Blood IS， PCS， and TMAO

更新时间：2025-03-04

- Clinical Efficacy of Renal Failure Enema as an Adjuvant Therapy for Chronic Kidney Disease Stages 3-4 and Its Effect on Blood IS， PCS， and TMAO
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 31, Issue 6, Pages: 164-170(2025)
- 作者机构：
  
  1.天津中医药大学，天津 300193
  2.天津市中医药研究院附属医院，天津 300120
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20250495
  CLC： R259;R969.4;R692
- Received：05 July 2024，
  
  Accepted：09 September 2024，
  
  Online First：21 October 2024，
  
  Published：20 March 2025
- 稿件说明：
移动端阅览
王婧,张勉之.肾衰灌肠液辅助治疗慢性肾脏病3~4期的临床疗效及对血清IS、PCS、TMAO的影响[J].中国实验方剂学杂志,2025,31(06):164-170.

WANG Jing,ZHANG Mianzhi.Clinical Efficacy of Renal Failure Enema as an Adjuvant Therapy for Chronic Kidney Disease Stages 3-4 and Its Effect on Blood IS， PCS， and TMAO[J].Chinese Journal of Experimental Traditional Medical Formulae,2025,31(06):164-170.
王婧,张勉之.肾衰灌肠液辅助治疗慢性肾脏病3~4期的临床疗效及对血清IS、PCS、TMAO的影响[J].中国实验方剂学杂志,2025,31(06):164-170. DOI： 10.13422/j.cnki.syfjx.20250495.

WANG Jing,ZHANG Mianzhi.Clinical Efficacy of Renal Failure Enema as an Adjuvant Therapy for Chronic Kidney Disease Stages 3-4 and Its Effect on Blood IS， PCS， and TMAO[J].Chinese Journal of Experimental Traditional Medical Formulae,2025,31(06):164-170. DOI： 10.13422/j.cnki.syfjx.20250495.

摘要

目的

观察肾衰灌肠液保留灌肠辅助治疗慢性肾脏病3~4期患者的临床疗效和对血清尿毒症毒素的影响。

方法

将2023年6月—2023年11月天津市中医药研究院附属医院肾病科住院部60例慢性肾脏病3~4期患者采用随机数表法分为对照组和观察组各30例。两组均行科内常规中西医对症治疗；观察组在对照组基础上加用院内制剂肾衰灌肠液100~200 mL，隔日1次。总疗程4周。比较两组治疗前后血肌酐（SCr）、尿素氮（BUN）、尿酸（UA）、24 h尿蛋白定量、血清尿毒症毒素硫酸吲哚酚（IS）、硫酸对甲酚（PCS）、氧化三甲胺（TMAO）的变化。计算中西医临床总有效率并记录不良反应情况。

结果

治疗前，两组患者基线水平具有可比性。治疗后观察组总有效率（80.0%，24/30）优于对照组（53.3%，16/30），差异具有统计学意义（

=2.267，

=0.023）。与本组治疗前比较，两组治疗后中医证候积分均较前降低，其中观察组差异具有统计学意义（

0.01）。与对照组治疗后比较，观察组患者中医证候积分明显降低且治疗前后差值更大（

0.05）。与本组治疗前比较，两组患者治疗后SCr均较治疗前下降（

0.05），观察组患者BUN水平明显降低（

0.05），观察组患者IS、PCS水平明显降低（

0.05，

0.01），与对照组治疗后比较，观察组患者IS水平明显降低（

0.05）。试验期间，两组患者均无不良反应发生。

结论

肾衰灌肠液能够辅助治疗慢性肾脏病CKD 3~4期患者，既能减缓肾功能进展，又能较好地下调尿毒症毒素含量，且对肾脏病患者中医证候有显著改善，值得临床应用推广。

Abstract

Objective

To observe the clinical efficacy of renal failure enema for retention enema as an adjuvant therapy in patients with chronic kidney disease stages 3-4 and its effect on serum uremic toxins including indoxyl sulfate （IS），p-cresol sulfate （PCS），and trimethylamine oxide （TMAO）.

Methods

A total of 60 patients with stage 3-4 chronic kidney disease in the Department of Nephrology，Affiliated Hospital of Tianjin Institute of Traditional Chinese Medicine from June 2023 to November 2023，were divided into a control group and an observation group. Each group consisted of 30 patients，and the random number table method was used for the division. Both groups received routine symptomatic treatment of traditional Chinese medicine （TCM） and Western medicine in the department. The observation group，based on the treatment of the control group，was additionally given 100-200 mL of the hospital-made renal failure enema capsules once every other day. The total treatment course was 4 weeks. The changes in serum creatinine （SCr），blood urea nitrogen （BUN），uric acid （UA），24-hour urine total protein quantification （24 h UTP），and serum uremic toxins such as IS，PCS，and TMAO were compared between the two groups before and after treatment. The total clinical effective rate of TCM and Western medicine was calculated and the adverse reactions were recorded.

Results

Before treatment，the baseline levels of the two groups were comparable. After treatment，the total effective rate of the observation group （80.0%，24/30） was superior to that of the control group （53.3%，16/30），and the difference was statistically significant （

2.267

，P=

0.023）. After treatment，the TCM pattern scores of the two groups were lower than before，and the constipation symptoms in the observation group were improved（

0.01）. Compared with the control group after treatment，the observation group showed decreased TCM syndrome scores，and the difference before and after treatment was larger （

0.05）. Compared with before treatment，the SCr in both groups decreased after treatment （

0.05）. BUN levels decreased in the observation group（

0.05），and IS and PCS levels decreased in the observation group（

0.05，

0.01）. Compared with the control group after treatment，the IS level of the observation group decreased （

0.05）. During the trial，no adverse reactions occurred in either group.

Conclusion

Renal failure enema can be used as an adjuvant therapy for patients with CKD stages 3-4. It can not only slow down the progression of renal function but also effectively down-regulate the levels of uremic toxins. In addition，it can significantly improve the TCM syndrome of kidney disease patients，which makes it worthy of clinical application and promotion.

关键词

Keywords

references

LUYCKX V A ， CHERNEY D ， BELLO A K . Preventing CKD in developed countries ［J］. Kidney Int Rep ， 2020 ， 5 （ 3 ）： 263 - 277 .

ULASI I I ， AWOBUSUYI O ， NAYAK S ， et al . Chronic kidney disease burden in low-resource settings：Regional perspectives ［J］. Semin Nephrol ， 2022 ， 42 （ 5 ）： 151336 .

GBD Chronic Kidney Disease Collaboration . Global，regional，and national burden of chronic kidney disease，1990-2017：A systematic analysis for the Global Burden of Disease Study 2017 ［J］. Lancet ， 2020 ， 395 （ 10225 ）： 709 - 733 .

JI A ， PAN C ， WANG H ， et al . Prevalence and associated risk factors of chronic kidney disease in an elderly population from eastern China ［J］. Int J Environ Res Public Health ， 2019 ， 16 （ 22 ）： 4383 .

DUAN J Y ， DUAN G C ， WANG C J ， et al . Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population：A cross-sectional survey ［J］. BMC Nephrol ， 2020 ， 21 （ 1 ）： 115 .

SPOTO B ， MATTACE-RASO F ， SIJBRANDS E ， et al . Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD ［J］. Clin J Am Soc Nephrol ， 2015 ， 10 （ 2 ）： 232 - 240 .

FRĄK W ， DĄBEK B ， BALCERCZYK-LIS M ， et al . Role of uremic toxins，oxidative stress，and renal fibrosis in chronic kidney disease ［J］. Antioxidants（Basel）， 2024 ， 13 （ 6 ）： 687 .

严梦婷，林钐，王江梅，等 . 高位结肠透析联合中药保留灌肠治疗慢性肾脏病4-5期湿浊证的临床观察［J］. 时珍国医国药， 2022 ， 33 （ 9 ）： 2198 - 2201 .

YAN M T ， LIN S ， WANG H M ， et al . Clinical observation of high level colonic dialysis combined with traditional chinese medicine retention enema for the treatment of dampness and turbidity syndrome in stage 4-5 of chronic kidney disease ［J］. Lishizhen Med Mater Med Res ， 2022 ， 33 （ 9 ）： 2198 - 2201 .

桑永浩，宋立群，贠捷，等 . 基于“肠肾轴”理论探讨通腑泄浊灌肠方治疗CKD 3~4期患者的临床疗效及对NLR的影响［J］. 中国实验方剂学杂志， 2024 ， 30 （ 21 ）： 227 - 233 .

SANG Y H ， SONG L Q ， YUN J ， et al . Clinical efficacy and effect on NLR of Tongfu Xiezhuo enema in treating patients with stage 3-4 CKD based on theory of gut-kidney axis ［J］. Chin J Exp Tradit Med Form ， 2024 ， 30 （ 21 ）： 227 - 233 .

赵亚，张勉之，樊威伟，等 . 国医大师张大宁治疗慢性肾功能衰竭微炎症状态经验［J］. 中华中医药杂志， 2021 ， 36 （ 9 ）： 5278 - 5280 .

ZHAO Y ， ZHANG M Z ， FAN W W ， et al . Experience of TCM master ZHANG Da-ning in treating chronic renal failure with micro inflammation ［J］. China J Tradit Chin Med Pharm ， 2021 ， 36 （ 9 ）： 5278 - 5280 .

STEVENS P E ， LEVIN A ， Kidney disease ： Improving global outcomes chronic kidney disease guideline development work group members . Evaluation and management of chronic kidney disease：Synopsis of the kidney disease：Improving global outcomes 2012 clinical practice guideline ［J］. Ann Intern Med ， 2013 ， 158 （ 11 ）： 825 - 830 .

ROUX-MARSON C ， BARANSKI J B ， FAFIN C ， et al . Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease ［J］. BMC Geriatr ， 2020 ， 20 （ 1 ）： 87 .

邱依婷，洪双双，刘芷秋，等 . 保肾方治疗气阴两虚、肾络瘀阻证糖尿病肾病Ⅳ期的随机对照试验［J］. 中国实验方剂学杂志， 2025 ， 31 （ 3 ）： 124 - 131 .

QIU Y T ， HONG S S ， LIU Z Q ， et al . Randomized controlled study of baoshen prescription in treating stage Ⅳ diabetic nephropathy in patients with syndromes of Qi-Yin deficiency and kidney collateral stasis and obstruction ［J］. Chin J Exp Tradit Med Form ， 2025 ， 31 （ 3 ）： 124 - 131 .

周冬林，陈宇，胡春安，等 . 大黄牡蛎灌肠方联合序贯式结肠透析治疗慢性肾脏病2~4期临床研究［J］. 中国中医药现代远程教育， 2024 ， 22 （ 14 ）： 118 - 121 .

ZHOU D L ， CHEN Y ， HU C A ， et al . Dahuang Muli enema prescription combined with sequential colon dialysis in the treatment of chronic kidney disease in 2-4 stage ［J］. Chin Med Mod Dis Educ China ， 2024 ， 22 （ 14 ）： 118 - 121 .

JI C ， LU F ， WU Y ， et al . Rhubarb enema increasing short-chain fatty acids that improves the intestinal barrier disruption in CKD may be related to the regulation of gut dysbiosis ［J］. Biomed Res Int ， 2022 ， 2022 ： 1896781 .

ODENWALD M A ， TURNER J R . The intestinal epithelial barrier：A therapeutic target？［J］. Nat Rev Gastroenterol Hepatol ， 2017 ， 14 （ 1 ）： 9 - 21 .

GONG J ， NOEL S ， PLUZNICK J L ， et al . Gut microbiota-kidney cross-talk in acute kidney injury ［J］. Semin Nephrol ， 2019 ， 39 （ 1 ）： 107 - 116 .

TANG W ， LI D Y ， HAZEN S L . Dietary metabolism，the gut microbiome，and heart failure ［J］. Nat Rev Cardiol ， 2019 ， 16 （ 3 ）： 137 - 154 .

TRANDAFIR M ， PIRCALABIORU G G ， SAVU O . Microbiota analysis in individuals with type two diabetes mellitus and end-stage renal disease：A pilot study ［J］. Exp Ther Med ， 2024 ， 27 （ 5 ）： 211 .

MILLER A W ， PENNISTON K L ， FITZPATRICK K ， et al . Mechanisms of the intestinal and urinary microbiome in kidney stone disease ［J］. Nat Rev Urol ， 2022 ， 19 （ 12 ）： 695 - 707 .

SUMIDA K ， LAU W L ， KALANTAR-ZADEH K ， et al . Novel intestinal dialysis interventions and microbiome modulation to control uremia ［J］. Curr Opin Nephrol Hypertens ， 2022 ， 31 （ 1 ）： 82 - 91 .

OLIVIER V ， DUNYACH-REMY C ， CORBEAU P ， et al . Factors of microinflammation in non-diabetic chronic kidney disease：A pilot study ［J］. BMC Nephrol ， 2020 ， 21 （ 1 ）： 141 .

BERTHOLD-PLUTA A ， PLUTA A ， GARBOWSKA M . The effect of selected factors on the survival of Bacillus cereus in the human gastrointestinal tract ［J］. Microb Pathog ， 2015 ， 82 ： 7 - 14 .

DURANTON F ， COHEN G ， DE SMET R ， et al . Normal and pathologic concentrations of uremic toxins ［J］. J Am Soc Nephrol ， 2012 ， 23 （ 7 ）： 1258 - 1270 .

MADERO M ， CANO K B ， CAMPOS I ， et al . Removal of protein-bound uremic toxins during hemodialysis using a binding competitor ［J］. Clin J Am Soc Nephrol ， 2019 ， 14 （ 3 ）： 394 - 402 .

LEE S ， SIRICH T L ， BLANCO I J ， et al . Removal of uremic solutes from dialysate by activated carbon ［J］. Clin J Am Soc Nephrol ， 2022 ， 17 （ 8 ）： 1168 - 1175 .

NAKANO T ， WATANABE H ， IMAFUKU T ， et al . Indoxyl sulfate contributes to mTORC1-induced renal fibrosis via the OAT/NADPH oxidase/ROS pathway ［J］. Toxins （Basel）， 2021 ， 13 （ 12 ）： 909 .

LANO G ， BURTEY S ， SALLÉE M . Indoxyl sulfate，a uremic endotheliotoxin ［J］. Toxins （Basel）， 2020 ， 12 （ 4 ）： 229 .

唐毅，田少江 . 硫酸吲哚酚促进慢性肾脏病患者急性冠脉综合征机制的研究进展［J］. 中国医学工程， 2024 ， 32 （ 7 ）： 55 - 60 .

TANG Y ， TIAN S J . Research progress on the mechanism of indophenol sulfate promoting acute coronary syndrome in patients with chronic kidney disease ［J］. China Med Engin ， 2024 ， 32 （ 7 ）： 55 - 60 .

SIRICH T L ， ARONOV P A ， PLUMMER N S ， et al . Numerous protein-bound solutes are cleared by the kidney with high efficiency ［J］. Kidney Int ， 2013 ， 84 （ 3 ）： 585 - 590 .

席永春，李慧，张紫媛，等 . 益肾汤结肠透析对慢性肾脏病3~4期患者IS、PCS的影响［J］. 中国中西医结合肾病杂志， 2021 ， 22 （ 12 ）： 1072 - 1074 .

XI Y C ， LI H ， ZHANG Z Y ， et al . The effect of Yishen Tang colon dialysis on IS and PCS in patients with chronic kidney disease in stages 3-4 ［J］. Chin J integr Tradit West Nephrol ， 2021 ， 22 （ 12 ）： 1072 - 1074 .

GATAREK P ， KALUZNA-CZAPLINSKA J . Trimethylamine N-oxide （TMAO） in human health ［J］. Excli J ， 2021 ， 20 ： 301 - 319 .

STEFANIA K ， ASHOK K K ， GEENA P V ， et al . TMAO enhances TNF- α mediated fibrosis and release of inflammatory mediators from renal fibroblasts ［J］. Sci Rep ， 2024 ， 14 （ 1 ）： 9070 .

Views

604

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanisms of Bushen Tongluo Jiangzhuo Prescription in Improving Renal Fibrosis in Rats with Chronic Kidney Disease Based on PI3K/Akt/mTOR Signaling Pathway

Clinical Efficacy and Effect on NLR of Tongfu Xiezhuo Enema in Treating Patients with Stage 3-4 CKD Based on Theory of Gut-kidney Axis

Jisheng Shenqi Pills Treat Chronic Kidney Disease in Rats via cAMP/AQP2/NLRP3 Pathway

Mechanism of Shenshuai Xiezhuo Decoction in Intervention of Chronic Kidney Disease Combined with Atherosclerosis Based on Regulation of PI3K/Akt/mTOR Signaling Pathway by miRNA126

Pinelliae Rhizoma and Its Prescription Compatibility for Depression Treatment： A Review

Related Author

WANG Jing

ZHANG Mianzhi

BAO Xincui

ZHAO Baosheng

QIN Lingling

WANG Haiyan

YANG Jing

WANG You

Related Institution

Affiliated Hospital of Tianjin Institute of Traditional Chinese Medicine

Tianjin University of Traditional Chinese Medicine

Mukogawa Women's University， Hyogo Prefecture

Dongzhimen Hospital， Beijing University of Chinese Medicine

Beijing Hospital of Traditional Chinese Medicine，Capital Medical University

AI脑图

AI问答

Address：No. 16, Nanxiaojie, Dongzhimennei, Beijing Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰